Dashboard
Manage Tickers

ABBV


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

abbvie-names-robert-a-michael-ceo-richard-a-gonzalez-to-become-executive-chairman
AbbVie Names Robert A. Michael CEO; Richar...
07/01/2024 12:11:06

As Previously Announced, Richard A. Gonzalez Retires as Chief Executive Officer to Become Executive ChairmanRobert A. Michael J...

reported-earlier-abbvies-epcoritamab-receives-ema-opinion-for-follicular-lymphoma-treatment
Reported Earlier, AbbVie's Epcoritamab Rec...
06/28/2024 07:38:13

AbbVie (NYSE:ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Us...

abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expansion-opportunities-underway
AbbVie/Genmab's Epkinly FDA Approval Is A ...
06/27/2024 17:22:09

The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...

looking-at-abbvies-recent-unusual-options-activity
Looking At AbbVie's Recent Unusual Options...
06/27/2024 16:03:25

abbvie-acquires-celsius-therapeutics-acquires-celsius-therapeutics-for-250m-in-cash
AbbVie Acquires Celsius Therapeutics Acqui...
06/27/2024 13:28:39

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for th...

allergan-aesthetics-debuts-all-payment-plans-allowing-members-to-pay-over-time-for-treatments-with-no-hard-credit-checks-participation-free-for-aesthetic-providers-increasing-affordability-for-botox-cosmetic-and-juvderm-fillers
Allergan Aesthetics Debuts Allē Payment Pl...
06/27/2024 12:32:58

abbvie-announced-that-the-us-fda-has-approved-epkinly-as-the-first-and-only-t-cell-engaging-bispecific-antibody-administered-subcutaneously-for-the-treatment-of-adults-with-relapsed-or-refractory-follicular-lymphoma
AbbVie Announced That The U.S. FDA Has App...
06/27/2024 06:50:48

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
06/25/2024 17:35:24

abbvies-parkinsons-disease-therapy-hits-fda-roadblock
AbbVie's Parkinson's Disease Therapy Hits ...
06/25/2024 13:58:23

AbbVie received an FDA Complete Response Letter for ABBV-951 (foscarbidopa/foslevodopa) due to third-party manufacturing issues...

abbvie-receives-a-complete-response-letter-from-us-fda--for-the-nda-for-abbv-951-for-the-treatment-of-motor-fluctuations-in-adults-with-advanced-parkinsons-disease
AbbVie Receives A Complete Response Letter...
06/25/2024 12:17:24

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspec...

check-out-what-whales-are-doing-with-abbv
Check Out What Whales Are Doing With ABBV
06/21/2024 19:17:55

heres-how-much-you-would-have-made-owning-abbvie-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
06/20/2024 19:30:32

cantor-fitzgerald-reiterates-overweight-on-abbvie-maintains-200-price-target
Cantor Fitzgerald Reiterates Overweight on...
06/20/2024 16:48:13

Cantor Fitzgerald analyst Louise Chen reiterates AbbVie (NYSE:ABBV) with a Overweight and maintains $200 price target.

nvidia-to-rally-around-53-here-are-10-top-analyst-forecasts-for-tuesday
Nvidia To Rally Around 53%? Here Are 10 To...
06/18/2024 13:44:27

piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-190
Piper Sandler Maintains Overweight on AbbV...
06/18/2024 12:31:58

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $1...

nvidia-abbvie-vertex-pharmaceuticals-and-an-oil-giant-cnbcs-final-trades
Nvidia, AbbVie, Vertex Pharmaceuticals And...
06/17/2024 12:47:19

On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named C...

abbvie-recommends-shareholders-reject-tutanotas-mini-tender-offer-to-purchase-up-to-250k-shares-of-common-stock-at-165-per-share-in-cash
AbbVie Recommends Shareholders Reject Tuta...
06/14/2024 20:11:52

AbbVie (NYSE:ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dat...

Core News & Articles
CNBC Halftime Report Final Trades: NVIDIA,...
06/14/2024 17:00:47

looking-into-abbvies-recent-short-interest
Looking Into AbbVie's Recent Short Interest
06/13/2024 13:45:15

abbvie-and--futuregen-biopharmaceutical-announce-license-agreement-to-develop--fg-m701-abbvie-to-receive-exclusive-global-license-futuregen-to-receive-150m-upfront-payment-and-up-to-156b-in-milestones
AbbVie And FutureGen Biopharmaceutical An...
06/13/2024 12:00:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)